Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese

References

• Uemichi T, Gertz M A, Benson M D. A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy. J Med Genet 1995; 32: 279–281
   PubMed Web of Science ®Google Scholar
• Jones L A, Skare J C, Cohen A S, Harding J A, Milunsky A, Skinner M. Familial amyloidotic polyneuropathy: a new transthyretin position 30 mutation (alanine for valine) in a family of German descent. Clin Genet 1992; 41: 70–73
   PubMed Web of Science ®Google Scholar
• Transthyretin (prealbumin). The Human Gene Mutation Database website. Available from http://www.hgmd.cf.ac.uk/ac/index.php. Accessed 26 April 2007.
   Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057–1062
   PubMed Web of Science ®Google Scholar
• Chou C T, Lee C C, Chang D M, Buxbaum J N, Jacobson D R. Familial amyloidosis in one Chinese family: clinical, immunological, and molecular genetic analysis. J Intern Med 1997; 241: 327–331
   PubMed Web of Science ®Google Scholar
• Lachmann H J, Booth D R, Bybee A, Hawkins P N. Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese–Taiwanese family. Hum Mutat 2000; 16: 180
   PubMedGoogle Scholar
• Wang Z, Zhang Y, Zhang W, Yuan Y. Clinical pathology and molecular genetics on familial amyloidotic polyneuropathy. Beijing Da Xue Xue Bao 2003; 35: 408–411
   PubMedGoogle Scholar
• Mak C M, Lam C W, Fan S T, Liu C L, Tam S C. Genetics of familial amyloidotic polyneuropathy in a Hong Kong Chinese kindred. Acta Neurol Scand 2003; 107: 419–422
   PubMed Web of Science ®Google Scholar
• Pica E C, Pramono Z A, Verma K K, San L P, Chee Y W. A novel transthyretin mutation V32A in a Chinese man with late-onset amyloid polyneuropathy. Muscle Nerve 2005; 32: 223–225
   PubMed Web of Science ®Google Scholar
• Lim A, Prokaeva T, Connor L H, Falk R H, Skinner M, Costello C E. Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid 2002; 9: 134–140
   PubMed Web of Science ®Google Scholar
• Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li Y F, Masuda Y, Ikeda S. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 1999; 6: 282–288
   PubMed Web of Science ®Google Scholar
• Booth D R, Tan S Y, Hawkins P N, Pepys M B, Frustaci A. A novel variant of transthyretin, 59Thr–>Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995; 91: 962–967
   PubMed Web of Science ®Google Scholar
• Sales-Luis Mde L, Conceicao I, de Carvalho M. Clinical and therapeutic implications of presymptomatic gene testing for familial amyloidotic polyneuropathy (FAP). Amyloid 2003; 10(Suppl. 1)26–31
   PubMedGoogle Scholar
• Hund E, Linke R P, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 2001; 56: 431–435
   PubMed Web of Science ®Google Scholar
• Cardoso I, Saraiva M J. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. Faseb J 2006; 20: 234–239
   PubMed Web of Science ®Google Scholar
• Palha J A, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti V, Merlini G, Saraiva M J. 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000; 156: 1919–1925
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle M A, Kelly J W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236–249
   PubMed Web of Science ®Google Scholar
• Tojo K, Sekijima Y, Kelly J W, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006; 56: 441–449
   PubMed Web of Science ®Google Scholar
• Ando Y. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Amyloid 2003; 10(Suppl. 1)55–66
   PubMedGoogle Scholar
• Gillmore J D, Hawkins P N. Drug Insight: emerging therapies for amyloidosis. Nat Clin Pract Nephrol 2006; 2: 263–270
   PubMedGoogle Scholar